Lv11
30 积分 2023-11-21 加入
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
9小时前
待确认
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
9小时前
已完结
Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?
6天前
已完结
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
8天前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
8天前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
9天前
已完结
Effects of folic acid combined with vitamin B12 on DVT in patients with homocysteine cerebral infarction
1个月前
已关闭
From A to E: Uniting vitamins against stroke risk—A systematic review and network meta‐analysis
1个月前
已完结
Bioequivalence of Celecoxib Capsules in Chinese Healthy Volunteers
4个月前
已完结
Bioequivalence Study of 1,500 mg Glucosamine Sulfate in Thai Healthy Volunteers
4个月前
已完结
皖公网安备34019202002308
